- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 249/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 249/12
Total number of patents in this class: 629
10-year publication summary
39
|
45
|
54
|
65
|
43
|
54
|
27
|
23
|
40
|
13
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
BASF SE | 20933 |
22 |
Theravance Biopharma R&D IP, LLC | 458 |
22 |
Synta Pharmaceuticals Corp. | 178 |
21 |
Bayer Pharma AG | 1052 |
16 |
Bayer AG | 3330 |
14 |
Ardea Biosciences, Inc. | 72 |
13 |
UPL Limited | 582 |
11 |
King Faisal University | 914 |
10 |
Yuhan Corporation | 226 |
10 |
The Regents of the University of California | 19918 |
9 |
FMC Corporation | 844 |
9 |
The General Hospital Corporation | 4733 |
8 |
F. Hoffmann-La Roche AG | 7925 |
7 |
Eli Lilly and Company | 3842 |
7 |
The University of Queensland | 660 |
7 |
Inflazome Limited | 85 |
7 |
Cv6 Therapeutics (NI) Limited | 32 |
7 |
Bayer Cropscience AG | 2035 |
6 |
President and Fellows of Harvard College | 5976 |
6 |
The Broad Institute, Inc. | 1808 |
6 |
Other owners | 411 |